Specific viral antibodies associate with anti-NMDAR encephalitis after herpes simplex encephalitis
Herpes simplex encephalitis (HSE) patients may develop secondary anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (NMDARE), associated with worsened long-term neurological outcome. Immunosuppressive treatment can limit NMDAR autoantibody-mediated pathology, but early predictive biomarkers for...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
November 2025
|
| In: |
Brain, behavior and immunity
Year: 2025, Volume: 130, Pages: 1-14 |
| ISSN: | 1090-2139 |
| DOI: | 10.1016/j.bbi.2025.106073 |
| Accesso online: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1016/j.bbi.2025.106073 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0889159125003083 |
| Note sull'autore: | Jakob Kreye, William R. Morgenlander, Manjusha Thakar, Poul M. Schulte-Frankenfeld, Sarah Schott, Isabel Bünger, Hans-Christian Kornau, Julia W. Angkeow, Sahana Jayaraman, Carolin Otto, Wiebke Hahn, Jan Lewerenz, Franziska S. Thaler, Mirjam Korporal-Kuhnke, Nico Melzer, Justina Dargvainiene, Christian G. Bien, Rose Kohlie, Erik Lattwein, Dietmar Schmitz, Peter A. Calabresi, Carlos A. Pardo, Harald Prüss, Klemens Ruprecht, H. Benjamin Larman |
| Riassunto: | Herpes simplex encephalitis (HSE) patients may develop secondary anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (NMDARE), associated with worsened long-term neurological outcome. Immunosuppressive treatment can limit NMDAR autoantibody-mediated pathology, but early predictive biomarkers for the risk of NMDARE are lacking. In a multicenter study, we performed unbiased antibody reactome profiling using Phage ImmunoPrecipitation Sequencing (PhIP-Seq). HSE patients with secondary NMDARE (n = 13) versus those without (n = 10) showed enhanced antibody responses against HSV-1, but not HSV-2, which comprised specific antibodies to five peptides of the HSV-1 UL42 and UL48 proteins. A score of these signature CSF antibodies identified HSE patients with secondary NMDARE with a sensitivity of 75%, a specificity of > 99%, a positive predictive value of 90%, a negative predictive value of > 97% and an odds ratio (OR) of 209 (CI: 28 - 1,582) across all individuals in this study, and with similar performance values in serum (>66%, >99%, >88%, >96%, OR 307 (15 - 6,089)). These signature antibodies represent a promising biomarker to identify HSE patients at risk for NMDARE development. In NMDARE patients without a history of HSE and in MS patients, no disease-associated HSV antibody reactivity patterns were detected. Furthermore, we introduced the Multiplexed Index Calculations of the Antibody Reactome (MICAR) metric to characterize proteomic targets of compartment-specific antibody responses, an approach that is applicable in neuroimmunology and other compartmentalized disease states. |
|---|---|
| Descrizione del documento: | Online veröffentlicht am: 11. August 2025 Gesehen am 28.05.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1090-2139 |
| DOI: | 10.1016/j.bbi.2025.106073 |